Medical Condition News

RSS

New titanium vertebral body replacement device from ulrich medical

ulrich medical USA, Inc., today announced the release of the Omni VBR Implant System, a new titanium vertebral body replacement device that is intended for use in the thoracic and lumbar spine (T1-L5) to replace a collapsed, damaged or unstable vertebral body due to tumor or trauma.

23 Apr 2012

Eating rice helps improve diet and manage weight

Eating white or brown rice helps improve diet and manage weight and other risk factors for disease, according to results from a study presented today at the Experimental Biology 2012 conference, in San Diego, CA.

23 Apr 2012

JT/Torii report positive results from ferric citrate Phase 3 study for hyperphosphatemia

Keryx Biopharmaceuticals, Inc., announced today that its Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd., has announced positive top-line results from a Phase 3 study of ferric citrate in Japan for the treatment of hyperphosphatemia in end-stage renal disease patients on hemodialysis.

23 Apr 2012

Cancer, genetic screenings under scrutiny

Various news outlets covered issues around cancer screening, diagnosis and treatment.

23 Apr 2012

Asubio commences SUN13837 Phase 2 clinical trial for acute spinal cord injury

Today, Asubio announced the initiation of a landmark Phase 2 clinical trial of SUN13837, an investigational medication being developed to improve neurological function in patients with newly diagnosed acute spinal cord injury.

23 Apr 2012

Enrollment complete in REPRISE I clinical trial for Lotus Aortic Valve System

Boston Scientific Corporation announces that it has completed enrollment in the REPRISE I clinical trial, which is designed to evaluate the acute safety of the Lotus Aortic Valve System, the first transcatheter aortic valve replacement (TAVR) device of its kind for patients with severe aortic valve stenosis that is both fully repositionable and retrievable prior to release.

23 Apr 2012

NEI awards Scripps Research $10.2M grant to develop new treatments for vision disorders

A team led by a scientist from The Scripps Research Institute has been awarded a five-year, $10.2 million grant from the National Eye Institute (NEI) to develop a new type of treatment for diabetic retinopathy, macular degeneration, and other common vision disorders.

23 Apr 2012

Poor sleep not a significant predictor of fibromyalgia pain intensity

Patients coping with the complex pain disorder fibromyalgia often have difficulty sleeping, and a new study published in The Journal of Pain reports that despite the negative quality of life implications, poor sleep is not a significant predictor of fibromyalgia pain intensity and duration.

23 Apr 2012

Nano-devices cross blood-brain barrier to deliver drug to treat cerebral palsy

A team of scientists from Johns Hopkins and elsewhere have developed nano-devices that successfully cross the brain-blood barrier and deliver a drug that tames brain-damaging inflammation in rabbits with cerebral palsy.

23 Apr 2012

Opiate addiction disorders associated with opioid-induced hyperalgesia

Patients with addictive disorders who take methadone or other opioid medications for pain will experience heightened sensitivity to pain, known as hyperalgesia, and new research published in The Journal of Pain shows that the condition does not improve over the course of treatment.

23 Apr 2012

Intrinsically disordered protein responsible for inactivating BK channel

Tiny pores, or channels, embedded in cell membranes are critical to the healthy functioning of cells. Charged atoms, or ions, move through these channels to generate the electrical signals that allow cells to communicate with one another.

23 Apr 2012

Enrollment complete for In-tunnel SeptRx European PFO Trial in Europe

SeptRx, an emerging medical device company that has developed the SeptRx Intrapocket PFO Occluder (IPO), reported today that it has completed enrollment for its "InterSEPT" (In-tunnel SeptRx European PFO Trial) clinical trial in Europe, and has entered into a partnership with CoRRect Medical GmbH for commercial distribution in Germany and Switzerland of the SeptRx IPO.

23 Apr 2012

ActiViews CT-Guide Needle Guidance System for liver interventions receives FDA 510(k) clearance

ActiViews, Inc, a company pioneering the development of simple, accurate, and cost-effective surgical navigation solutions, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its flagship product, CT-Guide Needle Guidance System, for liver interventions.

23 Apr 2012

OncoSec reports positive interim data from ElectroChemotherapy Phase IV head and neck cancer study

OncoSec Medical Inc., which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, today announced positive interim analysis of data from 81 subjects in a Phase IV study of primary and locally recurrent squamous cell carcinoma of the head and neck (HNSCC) treated with OMS ElectroChemotherapy in Europe.

23 Apr 2012

FDA extends review period for linaclotide NDA to treat constipation

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) notified the companies that it will require a three-month extension to complete its review of the data supporting the New Drug Application (NDA) for linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC).

23 Apr 2012

Mod5 yeast prion contributes to cell survival under environmental stress

One of the greatest mysterious in cellular biology has been given a new twist thanks to findings reported in Science. Researchers at the RIKEN Brain Science Institute show that prions, proteins that transmit heritable information without DNA or RNA, can contribute to drug resistance and cellular adaptation. Their discovery of a yeast prion with these properties demonstrates the active role of the prion conversion in cellular fitness adaptation, providing new insights into the potentially broader function of prions in living organisms.

23 Apr 2012

Sports medicine expert to present ‘Models of Injury Prevention’ at AMSSM conference

Roald Bahr, MD, PhD, will be presenting "Models of Injury Prevention" at the 21st American Medical Society for Sports Medicine Annual Meeting in Atlanta, GA on Saturday, April 21, 2012.

23 Apr 2012

AMSSM addresses strategies for injury prevention in young throwers

Tracy R. Ray, MD, delivered the Hough Memorial Lecture entitled "Pitch Counts: Can we prevent youth throwing injuries" at the 21st American Medical Society for Sports Medicine Annual Meeting in Atlanta, Ga. on Saturday, April 21, 2012.

23 Apr 2012

South African sports medicine expert to present at AMSSM annual meeting

South African sports medicine expert Martin Schwellnus, MD, PhD will be presenting "Born to Break Down? Genetics in Soft Tissue Injuries" at the 21st American Medical Society for Sports Medicine Annual Meeting in Atlanta, GA on April 22, 2012.

23 Apr 2012

Moxonidine drug can improve heart function and reduce blood pressure

Heart failure is the most common cause of death throughout the world, typically the result of chronic high blood pressure, also known as hypertension. As a result, research efforts have focused on an array of approaches aimed at preventing and treating high blood pressure. Recently, Japanese researchers examined the utility of an anti-hypertensive drug, moxonidine, which acts on the imidazoline receptors in the cardiovascular center of the brainstem.

23 Apr 2012